Dougherty T J
Dept of Radiation Medicine, Roswell Park Memorial Institute.
Oncology (Williston Park). 1989 Jul;3(7):67-73; discussion 74, 77-8.
Photodynamic therapy (PDT) uses drugs which, while pharmacologically inactive, can be activated in vivo by visible or near infrared light to produce a local toxic reaction (photosensitizers). Photofrin II (PII) is a mixture of oligomeric porphyrins which accumulate and are retained over several days in all malignant tissue at levels generally higher than surrounding epithelial tissues. Following activation by red light, generally obtained from a laser and delivered by simple quartz fiber optics, PII produces a photochemical generation of cytotoxic singlet oxygen that destroys the tissue in which it resides. Several thousand cancer patients with both early and advanced tumors have been treated to date with encouraging results. Phase III comparative, controlled clinical trials are underway for photodynamic treatment of tumors of the bladder, esophagus, and bronchus.
光动力疗法（PDT）使用的药物在药理上无活性，但可在体内被可见光或近红外光激活，从而产生局部毒性反应（光敏剂）。卟吩姆钠（PII）是一种寡聚卟啉混合物，它在所有恶性组织中蓄积并能保留数天，其水平通常高于周围上皮组织。在通常由激光产生并通过简单石英光纤传输的红光激活后，PII会光化学产生细胞毒性单线态氧，从而破坏其所在的组织。迄今为止，已有数千名患有早期和晚期肿瘤的癌症患者接受了治疗，结果令人鼓舞。针对膀胱、食管和支气管肿瘤的光动力治疗，三期比较性对照临床试验正在进行。
